In January, 2005, a 58-year-old woman presented complaining of bilateral sudden painless loss of vision, followed by perception of fl oaters. She had a history of colon carcinoma 2 years previously, and had been diseasefree since her treatment. Her visual acuity was 20/100 in the right eye and 20/40 in the left. Fundus examination showed scattered multiple choroidal infarcts bilaterally in the posterior pole surrounding the macular area (fi gure A). A 2+ vitreal fl are was also seen bilaterally. Fluorescein angiography showed hypofl uoresence at the infarcted sites in early stages and hyperfl uoresence at the late stages. Physical examination showed only a grade 2/6 systolic murmur of the heart. Two-dimensional transoesophageal echocardiography showed mobile vegetations of the mitral valve. Extensive laboratory blood tests, including tumour markers, C-reactive protein, fi brinogen, rheumatoid factor, antinuclear antibodies, anti-double-stranded DNA antibodies, antineutrophil cytoplasmic antibodies, and C3 and C4 complement components, showed only a mild prolongation of activated partial thromboplastin time (37 s). Serological tests for bacterial and viral infections were negative. Long-duration incubation of blood and aqueoushumour cultures were negative. Abdominal ultrasonography, CT of the chest and abdomen, brain MRI, carotid doppler tests, and colonoscopy showed no abnormalities. Further testing gave a positive result for IgG anticardiolipin antibodies (IgG-aCL), with a binding index of 370 (index cut-off =100, which corresponds to the cut-off of 15–20 GPL units of the commercially available assays) on a highly sensitive, specifi c, and inter nationally accepted ELISA. She was also positive for IgM-aCL and lupus anticoagulant (ratio: 1·65; normal <1·2) by the diluted Russell’s viper venom test (HemosIL, Instrumentation Laboratory Company, Lexington, MA, USA). The IgG-aCL titre remained positive 6 weeks and 12 weeks after the fi rst test (binding index 456 and 379, respectively, which correspond to more than 80 GPL units with the conventional assays). Antiphospholipid syndrome (APS) accom panied by non-bacterial thrombotic endocarditis was considered, and anticoagulant treatment with acenocoumarol was started with target INR 3·0–3·5. After 4 weeks, her visual acuity had improved (right eye 20/50; left eye 20/25). Vitreal fl are disappeared 6 weeks after presentation. 8 weeks after her intitial presentation, transoesophageal echocardiography and cardiac MRI showed no abnormalities. At a 5-month follow-up appoint ment, her visual acuity had improved further (right eye 20/25; left eye 20/20). 1 year after her initial presentation, the patient’s fundus (fi gure B), visual acuity, and general health have remained stable. When last seen in May, 2006, she remained well. APS is an autoimmune disorder characterised by arterial or venous thrombosis, recurrent fetal loss, and circulating antiphospholipid antibodies. It has been implicated in a range of ocular disorders. The clinical features of ocular involvement seem to be diff erent in primary and secondary APS—vasculopathic eye disease involving retinal and choroidal vessels seems to be typical in the primary form, whereas retinal thrombosis is more common in APS associated with systemic lupus erythematosus. In our patient, APS was the main mechanism leading to choroidal infarction. Non-bacterial thrombotic endocarditis can accompany malignant disorders whether or not they are associated with APS. In our case, we were not able to detect a relapse of cancer, which is in accordance with a prospective study showing high aCL titres in some cancer patients even during clinical remission of the disease. These associations suggest the need for thorough followup for thrombotic events in aCL-positive cancer. Additionally, unexplained ocular manifestations should alert physicians for APS presence because the ophthalmological symptoms can be the fi rst clinically evident manifestations of this disorder, and anticoagulant treatment should be started as soon as possible.
Read full abstract